358 studies found for:    "Expanded Access" [STUDY-TYPES]
Show Display Options
Rank Status Study
1 Available Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia
Condition: Congenital Hyperinsulinism
Intervention: Drug: Pasireotide
2 Available CU Programme of Idarucizumab for Japanese Patients
Condition: Hemorrhage
Intervention: Drug: idarucizumab
3 Available C11 Sodium Acetate PET/CT Imaging of PCa
Condition: Prostate Cancer
Intervention: Drug: Carbon-11 Sodium Acetate
4 Available Open-label Evaluation of Polymyxin B Hemoperfusion for Septic Shock
Conditions: Septic Shock;   Endotoxemia
Intervention: Device: TORAYMYXIN PMX-20R
5 Temporarily not available Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC
Conditions: Neoplasms;   Carcinoma, Non-Small-Cell Lung
Intervention: Drug: crizotinib
6 Available Study of Allogeneic EBV-CTLs in EBV-Associated Lymphomas and Lymphoproliferative Disorders
Conditions: Epstein-Barr Virus-Associated Lymphoproliferative Disorder;   Epstein-Barr Virus Lymphoma;   Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder
Intervention: Biological: Epstein-Barr Virus Cytotoxic T Lymphoctyes (EBV-CTLs)
7 Temporarily not available Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Ocrelizumab
8 Available Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: Abemaciclib
9 Available An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Lung Cancer;   Advanced Malignancies;   Carcinoma
Intervention: Drug: Brigatinib
10 Available Intravenous Fish Oils in the Treatment of Parenteral Nutrition Liver Injury
Conditions: Cholestasis;   Total Parenteral Nutrition-induced Cholestasis
Intervention: Drug: Omegaven
11 Available Compassionate Use of Omegaven
Condition: Cholestasis
Intervention: Dietary Supplement: Omegaven
12 Approved for marketing Expanded Access of Pimavanserin for Patients With PD Psychosis
Condition: Parkinson's Disease Psychosis
Intervention: Drug: Pimavanserin tartrate
13 Temporarily not available An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study
Condition: HIV
Intervention: Drug: PRO 140
14 No longer available Expanded Access to ANG1005 for Individual Patients
Conditions: Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Breast Cancer With Recurrent Brain Metastases;   Leptomeningeal Carcinomatosis
Intervention: Drug: ANG1005
15 Available Clinical Use of a Magnetic Anal Sphincter Augmentation Device, Trade Name FENIX
Condition: Fecal Incontinence
Intervention: Device: magnetic anal sphincter augmentation for fecal incontinence
16 Available Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
Condition: Non-Hodgkin's B-cell Lymphoma
Intervention: Drug: MT-3724
17 No longer available SARC021C: A Continuation Study of TH-CR-406/SARC021
Condition: Soft Tissue Sarcoma
Intervention: Drug: Th-302
18 Available Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients With Inoperable, Somatostatin Receptor Positive, Midgut Carcinoid Tumors, Progressive Under Somatostatin Analogue Therapy
Condition: Midgut Carcinoid Tumor
Intervention: Drug: 177Lu-DOTA0-Tyr3-Octreotate
19 Available Compassionate Use of MitoGel in Upper Tract Urothelial Carcinoma
Condition: Urothelial Carcinoma Ureteral Location
Intervention: Drug: MitoGel
20 Available Low-profile Visualized Intraluminal Support -HUD
Condition: Giant Wide Necked Aneurysms
Intervention: Device: Low Profile Visualized Intraluminal Support Device

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years